Value
7.6/10data confidence 100%| Component | Sub-score |
|---|---|
| P/E | 2.8 |
| P/S | 10.0 |
| EV/EBITDA | 2.8 |
| Fwd P/E | 8.8 |
| PEG | 10.0 |
| Analyst target | 9.0 |
- ▸Forward P/E: 12.6x
- ▸PEG: 0.09
- ▸Attractively valued
ALHC · Why this verdict
Why Alignment Healthcare (ALHC) is rated BUY WAIT
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictBUY WAIT
Overall score6.0/10
ConfidenceMEDIUM
MacroRISK_OFF
TrendMatrix Research · core thesis
Engine thesis — one sentence
Alignment Healthcare is growing revenues at 33% year-over-year with a strong analyst consensus (26% upside to target) and a favorable reward-to-risk ratio, but overall quality remains just below the minimum investment threshold — held back by near-zero operating margins and the complete absence of revenue diversification beyond government contracts; high short interest of 13% adds a binary volatility overlay to any catalyst.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
Overall quality remains just below the minimum investment floor despite anomalously high cash conversion relative to net income; near-zero operating margins and the absence of a durable competitive advantage mean the business is not yet generating sustainable economics at scale. Quality breakdown | Quality should improve above the minimum floor, which requires the overall quality score to exceed 4.0 for 2 consecutive quarters — likely contingent on operating margins becoming meaningfully positive. | →Stable |
| CounterHigh-growth healthcare companies frequently operate at thin margins while prioritizing member growth; sustained 33% revenue expansion may drive operating leverage as fixed costs are spread across a larger revenue base. | ||
Revenue has expanded 33% year-over-year, reflecting strong membership or patient volume growth that places this company well above typical healthcare services sector growth rates; the expansion has supported 3 consecutive quarters of positive earnings surprises. Growth breakdown | Revenue growth should remain above 20% year-over-year for 2 consecutive quarters to confirm the trajectory is durable rather than a cyclical surge. | →Stable |
| CounterRevenue is substantially dependent on CMS government contracts, which means the growth rate is vulnerable to policy changes, reimbursement rate resets, or contract non-renewal that can interrupt the trajectory abruptly. | ||
Substantially all of the company's revenues depend on CMS government contracts, creating a single-counterparty concentration that exposes the business to abrupt revenue disruption if reimbursement parameters are changed or contracts are restructured. Bear case | If diversification proceeds, non-CMS revenue should grow to represent more than 20% of total within 12 months, reducing the binary policy risk. | →Stable |
| CounterMulti-year value-based care agreements with CMS can provide revenue visibility over extended horizons, partially mitigating the year-to-year renewal risk inherent in government-contract exposure. | ||
Short interest at 13% of float stands in sharp contrast to bullish analyst consensus with 26% upside to target; this creates a binary setup where fundamental confirmation could force a substantial short-covering rally, while any earnings or policy disappointment could accelerate selling from both shorts and longs. Key risks | Short interest should fall below 6% of float as fundamental delivery continues and the short thesis loses its supporting evidence. | →Stable |
| CounterThe 13% short interest may reflect informed institutional awareness of reimbursement risk and quality concerns that analyst price targets have not yet incorporated; the short position may be the better-informed side of the trade. | ||
Overall quality remains just below the minimum investment floor despite anomalously high cash conversion relative to net income; near-zero operating margins and the absence of a durable competitive advantage mean the business is not yet generating sustainable economics at scale.
→StableQuality breakdown
- Expectation
- Quality should improve above the minimum floor, which requires the overall quality score to exceed 4.0 for 2 consecutive quarters — likely contingent on operating margins becoming meaningfully positive.
CounterHigh-growth healthcare companies frequently operate at thin margins while prioritizing member growth; sustained 33% revenue expansion may drive operating leverage as fixed costs are spread across a larger revenue base.
Revenue has expanded 33% year-over-year, reflecting strong membership or patient volume growth that places this company well above typical healthcare services sector growth rates; the expansion has supported 3 consecutive quarters of positive earnings surprises.
→StableGrowth breakdown
- Expectation
- Revenue growth should remain above 20% year-over-year for 2 consecutive quarters to confirm the trajectory is durable rather than a cyclical surge.
CounterRevenue is substantially dependent on CMS government contracts, which means the growth rate is vulnerable to policy changes, reimbursement rate resets, or contract non-renewal that can interrupt the trajectory abruptly.
Substantially all of the company's revenues depend on CMS government contracts, creating a single-counterparty concentration that exposes the business to abrupt revenue disruption if reimbursement parameters are changed or contracts are restructured.
→StableBear case
- Expectation
- If diversification proceeds, non-CMS revenue should grow to represent more than 20% of total within 12 months, reducing the binary policy risk.
CounterMulti-year value-based care agreements with CMS can provide revenue visibility over extended horizons, partially mitigating the year-to-year renewal risk inherent in government-contract exposure.
Short interest at 13% of float stands in sharp contrast to bullish analyst consensus with 26% upside to target; this creates a binary setup where fundamental confirmation could force a substantial short-covering rally, while any earnings or policy disappointment could accelerate selling from both shorts and longs.
→StableKey risks
- Expectation
- Short interest should fall below 6% of float as fundamental delivery continues and the short thesis loses its supporting evidence.
CounterThe 13% short interest may reflect informed institutional awareness of reimbursement risk and quality concerns that analyst price targets have not yet incorporated; the short position may be the better-informed side of the trade.
Per-dimension breakdown
Quality
4.5/10data confidence 100%| Component | Sub-score |
|---|---|
| ROE | 6.7 |
| ROA | 2.0 |
| Gross margin | 0.0 |
| Op margin | 1.3 |
| Net margin | 0.4 |
| Current ratio | 6.1 |
| FCF quality | 10.0 |
| Moat | 6.0 |
| Piotroski F | 7.8 |
- ▸Excellent cash conversion: 463% FCF/NI
- ▸Strong Piotroski F-Score: 7/9
Growth
10.0/10data confidence 67%| Component | Sub-score |
|---|---|
| Rev growth | 10.0 |
| EPS growth | 10.0 |
- ▸Strong growth: 32% YoY
Momentum
3.3/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 4.5 |
| MACD | 9.1 |
| OBV | 1.5 |
| MA position | 1.0 |
| Volume | 0.4 |
- ▸Volume distribution (falling OBV)
- ▸Below 200-MA, MA slope -9.4%/30d — confirmed downtrend
Sentiment
7.6/10data confidence 100%| Component | Sub-score |
|---|---|
| LLM sentiment | 6.2 |
| Analyst rating | 7.2 |
| Price target | 9.5 |
- ▸Analyst upside: 50%
Insider
4.7/10data confidence 100%| Component | Sub-score |
|---|---|
| materiality | 2.0 |
| insider conviction | 2.0 |
| holder change | 7.7 |
| notable moves | 7.0 |
- ▸Heavy insider selling — $13,712,577 (0.808% of mkt cap)
- ▸Institutions accumulating
Peer rank
3.9/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 2.3 |
| quality rank | 5.9 |
| growth rank | 7.3 |
- ▸Superior ROE vs peers
Technical
3.4/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 5.3 |
| support resistance | 2.2 |
| 52w position | 0.0 |
| gap | 6.0 |
Risk (lower is worse)
4.8/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 3.7 |
| days to cover | 9.1 |
| volatility | 0.0 |
| put call | 10.0 |
| implied vol | 0.0 |
| beta | 6.4 |
| debt equity | 4.5 |
- ▸High IV: 100%
- ▸Concentration risks: 1 HIGH, 1 MED (10-K Item 1A — sized via position_sizing, validated via buy_confidence)
Catalyst
7.6/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 10.0 |
| earnings timing | 5.0 |
| surprise avg | 10.0 |
| news activity | 8.0 |
- ▸Strong earnings: 3B/0M
- ▸Earnings today
How the verdict was assembled
Engine trigger
Earnings today. Wait until post-earnings.
Engine technical detail
verdict_path:
L3:NEWS_BLOCK|ENTRY_STICKY:WITHIN_BANDPassed (5)
- ASYMMETRY:2.1>=1.5
- 8K:CLEAN
- NEWS_EVENTS:NONE_RECENT
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (4)
- MOMENTUM:3.3<4.5
- INSIDER:0.81%=EXTREME
- DEATH_CROSS:HARD_BLOCK
- EARNINGS_PROXIMITY:0d<=7d
Warning (0)
none
Reward-to-Risk
2.06
Upside
+30.9%
Downside
15.0%
Sizing output
STARTER
SetupRecovery — Death cross but MACD improving, RSI 42
EdgeInst Constrain — Small cap ($1.7B) below institutional reach
SuitabilitySpeculative — Drawdown -67% (>40% off 52w high)
Investment implication
A recent news event triggered an L3 news-block on the verdict path. Trigger: Earnings today. Wait until post-earnings. The 10-dimension scores remain Growth at 10.0 (strongest), but MOMENTUM:3.3<4.5 also fails — the news block is the proximate trigger, not the sole driver.
The strongest dimensions are Growth at 10.0, Value at 7.6, and Sentiment at 7.6; the weakest are Momentum at 3.3, Technical at 3.4, and Peer rank at 3.9. The V9 engine flagged 4 failed gates, producing an asymmetric reward-to-risk of 2.06 and an engine sizing output of STARTER.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Accelerating Revenue Growth
Trip ifRevenue growth falls below 15% year-over-year for 2 consecutive quarters.
- P2Quality Below Floor Thin Margins
Trip ifOverall quality score rises above 4.0 for 2 consecutive quarters, indicating the quality floor has been cleared.
- P3Cms Contract Concentration Risk
Trip ifNon-CMS revenue grows above 20% of total revenue for 2 consecutive quarters.
- P4High Short Interest Binary Setup
Trip ifShort interest falls below 6% of float.